Pneumops 23 Dosage/Direction for Use

Injection Site and Route of Administration: This product is for intramuscular or subcutaneous injection (intramuscularly recommended) and the preferred administration site is the deltoid muscle of the lateral upper arm or lateral mid-thigh. Intravascular and intradermal injection is prohibited.
Dosage: Single dose (0.5 mL).
Revaccination: Persons at high risk (splenectomy) who were previously vaccinated over 5 years or with significant decreasing antibody titers (e.g., nephrotic syndrome, renal failure and organ transplantation) are recommended to revaccinate against pneumococcal diseases.
Children under 10 years old with nephrotic syndrome, splenectomy or sickle cell diseases are recommended to revaccinate 3-5 years later after the initial vaccination.
The immune persistence of this product has so far not demonstrated by any clinical study. The recommendations for revaccination previously mentioned are compiled based on the recommendations for subsequent doses of PPSV23 prescribed in the Prevention of Pneumococcal Diseases-Recommendations by the Advisory Committee on Immunization Practices (CDC, United States, 1997).